Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

rates (ORR), clinical benefit rate, duration of response, pharmacokinetics, safety, quality-of-life measurements, and pharmacoeconomic implications.  The study is also evaluating specific biomarker data to assess correlation with objective tumor response rates, progression-free survival, overall survival and selected toxicities.About Etirinotecan Pegol (NKTR-102)NKTR-102 is a new therapeutic option in development for advanced breast cancer.  It is the first long-acting topoisomerase I inhibitor with a non-overlapping mechanism of action with other agents used to treat breast cancer, which may mitigate potential cancer cross-resistance and reduce overlapping toxicities.  In November 2012, NKTR-102 was designated a Fast Track development program by the U.S. FDA for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with ATC.

NKTR-102 is believed to penetrate the vasculature of the tumor environment more readily than normal vasculature, increasing the concentration of active drug within tumor tissue to enhance anti-tumor activity. The unique PK profile of NKTR-102 provides continuous exposure of active drug throughout the entire chemotherapy cycle, with reduced peak exposures that can be associated with toxicities. In addition to metastatic breast cancer, NKTR-102 is also being evaluated for the treatment of ovarian, colorectal, glioma and lung cancers.

About Metastatic Breast CancerMore than one million women worldwide are diagnosed with breast cancer globally every year. (2) The chance of developing invasive breast cancer at some time in a woman's life is a little less than one in eight (12%). There are approximately 200,000 new cases of breast cancer in the United States and 430,000 in Europe each year. (3) Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.

Anthracyclines
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014   Metanome, Inc. ... comprehensive metagenomic services and data analysis, was the genomic ... ) Phase I/II clinical trial of SER 109, ... recurrent Clostridium difficile infections (CDI). ... Seres Health,s R&D and clinical programs. Such genomic characterization ...
(Date:10/25/2014)... , October 24, 2014 ... http://www.researchandmarkets.com/research/wdq92g/global_and ) has announced the addition of ... Report 2014"  report to their offering.  ... Global and Chinese Acne Medication Industry Report ... on the current state of the global ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... Nov. 3, 2010 Telik, Inc. (Nasdaq: TELK ... $0.09 per share, for the third quarter ended September 30, ... $0.11 per share, for the comparable period in 2009. ... costs and expenses were $4.7 million, compared with $6.2 million in ...
... N.J., Nov. 3, 2010 Regado Biosciences, a privately ... active control agents, announced that Ellen McDonald, MBA, Senior ... at IMPACT 2010 held at the Pennsylvania Convention Center ... at 11:13 a.m. EST on Wednesday, November 10 in ...
Cached Medicine Technology:Telik Announces Third Quarter 2010 Financial Results 2Telik Announces Third Quarter 2010 Financial Results 3Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania 2Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania 3
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Medical Solutions , the ... to announce that our co-founder and CFO, Scott ... Staffing 100 for 2014. Anderson was also named ... people in the staffing industry,” in 2013.     , ... healthcare staffing company in the U.S., was named ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... new diagnostic technique capable of producing three-dimensional, in-depth ... number of women who are recalled for additional ... clinical trial being conducted at Emory University Breast ... annual meeting of the Radiological Society of North ...
... Procedures through the Belly Button: Scar-Free ... ... Nov. 28 Cleveland Clinic urologists recently,performed a series of ... repair), ileal ureter replacement, and psoas hitch uretero-,neocystostomy (for ureteral ...
... Medical Entrepreneurs is Only a Phone Call or ... care entrepreneurs,working outside the traditional health insurance payment ... computer software to make,medical care more accessible and ... the National Center for Policy Analysis (NCPA)., http://www.ncpa.org/pub/st/st305/st305.pdf ...
... Be Presented at 9:00 a.m. ... ... The Trade, Health and Environment,Impact Project, a collaboration of community organizations ... East Yard Communities for Environmental Justice, Center for,Community Action & Environmental ...
... and clinical ... development experience to Celator., PRINCETON, N.J., ... develop combination chemotherapies to,treat different types of cancer, today ... R. Appelbaum, M.D., head of the,University of Washington School ...
... that had the neurological disease, researchers say , WEDNESDAY, ... to a possible treatment for amyotrophic lateral sclerosis (ALS), ... a protein normally found in human cells into mice ... The team found that the treatment delayed symptoms and ...
Cached Medicine News:Health News:'Stereo' mammography takes breast imaging to a new dimension 2Health News:World Firsts by Cleveland Clinic Urologists 2Health News:NCPA Study: Government, Insurers Keep Medicine in Stone Age 2Health News:NCPA Study: Government, Insurers Keep Medicine in Stone Age 3Health News:Los Angeles Port Pollution, Int'l Trade & Goods Movement Conference This Weekend 2Health News:Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals 2Health News:Cell Protein Might Help Treat ALS 2
96-Well PCR Plate Sealing Mat...
Easy to pierce, remove using foil stripper...
Inquire...
... Sealing Foil and Heat Sealing Film each provide ... safe and easy sample storage. In automated procedures ... standard pipette tips. The Heat Sealing Film is ... the plates. Heat Sealing Foil is removed by ...
Medicine Products: